Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 2

1(25.0%)

N/A

1(25.0%)

4Total

Phase 1(2)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03592771Not ApplicableCompleted

THRIVE Breast Cancer App Study

Role: collaborator

NCT02906852Completed

Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing

Role: collaborator

NCT00800345Phase 1Completed

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

Role: lead

NCT01506596Phase 2Completed

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Role: lead

NCT01388647Phase 1Terminated

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Role: lead

All 5 trials loaded